RxDoctor Payments Data

Abhinav Ohri

Sleep Medicine · Kingman, AZNPI 1306285432

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,212 of the $3,029 with a category attached, or 73.0%. Livanova USA, Inc. accounts for 86.3% of it on its own, with 5 other manufacturers making up the rest. 2023 is the largest year on record at $1,684, more than ten times the $96 reported in 2019.

$3,029in general payments, 2019–2025

Across 18 payments — averaging $168.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • Biogen$150
  • UCB, Inc.$115
  • Lilly USA, LLC$68
  • Nevro Corp.$58
  • Genentech USA, Inc.$25

What the payments were for

  • Consulting fees$1756%
  • Travel & lodging$2,21273%
  • Food & beverage$64221%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,029 in reported general payments places this provider in the 55th percentile of 47 sleep medicine providers in Arizona.

See all sleep medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$156,526
Medicare patients
438
Services billed
2,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$33,986
Nurtec OdtRimegepant Sulfate11$20,308
UbrelvyUbrogepant18$19,819
BriviactBrivaracetam12$16,733
Duloxetine Hcl149$6,598
Lacosamide40$6,243
Memantine Hcl228$5,363
Levetiracetam133$5,179
Gabapentin176$3,270
Carbidopa-Levodopa ErCarbidopa/Levodopa32$2,669
Donepezil Hcl132$2,489
Pregabalin73$2,458
Lamotrigine92$2,168
Divalproex Sodium35$2,141
Topiramate117$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$115$16,73312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 47 sleep medicine providers in Arizona.

Other sleep medicine in Kingman

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →